Centre for Applied Health Economics, Griffith University, Brisbane, Qld, Australia.
Centre for Applied Health Economics, Griffith University, Brisbane, Qld, Australia.
Heart Lung Circ. 2021 Aug;30(8):1207-1212. doi: 10.1016/j.hlc.2020.10.029. Epub 2021 Feb 23.
To estimate the incidence-based, lifetime costs of health care and productivity losses associated with cardiovascular disease (CVD) using hospital admission data from Queensland, Australia.
Retrospective analysis of data on CVD health care use sourced from Queensland Hospital Admitted Patient Data Collection (QHAPDC), Emergency Department Data Collection (EDDC), Medicare Benefits Schedule (MBS) and the Pharmaceutical Benefits Scheme (PBS). Costs were estimated from the societal perspective. Study participants included patients who were first admitted to any Queensland hospital in 2010 for a CVD-related treatment. Subsequent admissions of these patients were followed until December 2015. The present value of incidence-based lifetime costs per patient were used to estimate the total costs for Australia. All costs were presented in Australian dollars at 2019 prices.
The estimated lifetime health care cost of CVD was AUD$65,700 per person. Productivity loss cost was higher at AUD$75,200 per person, and total indirect lifetime costs were $140,900 per person. Scaling these costs up for the Australian population, the estimated incidence-based lifetime CVD costs for Australia were $60.5 billion ($28.2 billion in direct costs and $32.3 billion in indirect costs).
Incidence-based lifetime indirect costs of CVD were higher than the direct costs. The life-time cost structure suggests that economic benefits of health care interventions for cardiovascular diseases from a societal perspective should be at least twice as large than that from a health service perspective.
利用来自澳大利亚昆士兰州的医院入院数据,估算心血管疾病(CVD)相关医疗保健和生产力损失的终生基于发病率的成本。
对来源于昆士兰医院入院患者数据采集系统(QHAPDC)、急诊部数据采集系统(EDDC)、医疗保险福利计划(MBS)和药品福利计划(PBS)的 CVD 医疗保健使用数据进行回顾性分析。从社会角度估算成本。研究参与者包括 2010 年首次因 CVD 相关治疗而入住昆士兰州任何一家医院的患者。对这些患者的后续入院情况进行了随访,直到 2015 年 12 月。使用每位患者基于发病率的终生成本现值来估算澳大利亚的总成本。所有成本均以 2019 年价格的澳元表示。
CVD 的终生医疗保健成本估计为每人 65700 澳元。生产力损失成本更高,为每人 75200 澳元,总间接终生成本为每人 140900 澳元。将这些成本按澳大利亚人口规模进行推算,澳大利亚基于发病率的终生 CVD 成本估计为 605 亿澳元(直接成本为 282 亿澳元,间接成本为 323 亿澳元)。
基于发病率的 CVD 间接终生成本高于直接成本。终生成本结构表明,从社会角度来看,心血管疾病医疗保健干预的经济效益至少应该是从卫生服务角度来看的两倍。